References
- Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol. 2013;14:27–47.
- Virgili A, Borghi A, Toni G, et al. Prospective clinical and epidemiologic study of vulvar lichen sclerosus: analysis of prevalence and severity of clinical features, together with historical and demographic associations. Dermatology (Basel). 2014;228:145–151.
- Lansdorp CA, van den Hondel KE, Korfage IJ, et al. Quality of life in Dutch women with lichen sclerosus. Br J Dermatol. 2013;168:787–793.
- Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163:672–682.
- Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;12:CD008240.
- Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29:e1–e43.
- Virgili A, Borghi A, Toni G, et al. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol. 2014;171:388–396.
- Corazza M, Borghi A, Toni G, et al. Clobetasol propionate versus mometasone furoate in one-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol. 2016;30:956–961.
- Borghi A, Corazza M, Minghetti S, et al. Continuous vs. tapering application of the potent topical corticosteroid mometasone furoate in the treatment of vulvar lichen sclerosus: results of a randomized trial. Br J Dermatol. 2015;173:1381–1386.
- Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25:9–14.
- Greive KA, Barnes TM. Bioequivalence of 0.1% mometasone furoate lotion to 0.1% mometasone furoate hydrogel. Australas J Dermatol. 2016;57:e39–e45.
- Tan X, Feldman SR, Chang J, et al. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9:1263–1271.
- Tadicherla S, Ross K, Shenefelt PD, et al. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8:1093–1105.
- Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005; 53:S50–S58.
- Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008;68:453–466.
- Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35:S36–S44.
- Kirkland R, Pearce DJ, Balkrishnan R, et al. Critical factors determining the potency of topical corticosteroids. J Dermatol Treat. 2006;17:133–135.
- Korting HC, Maslen K, Gross G, et al. Vergleich der Wirksamkeit verschiedener topischer Glukokortikoidcremes und –salben im Vasokonstriktionstest: Überlegenheit von Hydrocortisonbutyrat gegenüber Hydrocortison. J Dtsch Dermatol Ges. 2005;3:348–353.